Peptide–Major Histocompatibility Complex class II (pMHCII)

The Peptide–Major Histocompatibility Complex class II (pMHCII) complex is a fundamental component of the adaptive immune system, primarily expressed on professional antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells (UniProt, P01903). It is formed by the association of an alpha and a beta chain of the MHC class II molecule with a peptide fragment derived from extracellular proteins via the endocytic pathway. This complex is specifically recognized by the T-cell receptor (TCR) of CD4+ T lymphocytes, a process that is essential for orchestrating immune responses against pathogens and maintaining self-tolerance (PubMed, PMID: 25246482). Dysregulation of pMHCII-mediated antigen presentation is a hallmark of various autoimmune disorders, such as Type 1 Diabetes and Rheumatoid Arthritis, where self-peptides are inappropriately presented, leading to tissue destruction. Consequently, pMHCII is a major focus for drug development, with strategies ranging from peptide-based vaccines for desensitization to the use of MHC-mimetics and blocking antibodies to modulate T-cell activity in cancer and autoimmunity (NCBI, NBK27156).

Other names

HLA class II-peptide complexMHC II-peptide complexAntigen-MHC II complexpMHCII complexMHC class II-antigen complex

Therapeutic agents targeting the pMHCII complex function through several mechanisms: competitive inhibition where decoy peptides (e.g., Glatiramer acetate) displace pathogenic self-peptides from the MHC II binding groove; TCR-blockade using monoclonal antibodies or soluble TCR-mimetics to prevent T-cell recognition; and the induction of immune tolerance through the presentation of specific peptides in a non-inflammatory context to promote regulatory T-cell (Treg) differentiation (StatPearls, PMID: 30725703; Nature Reviews Immunology, PMID: 29379212).